160 likes | 278 Views
General classes of vaccines. An induced mobilization of the immune response for the purpose of therapeutic benefit. Preventative: infectious agents Therapeutic: cancer. General classes of vaccines.
E N D
General classes of vaccines An induced mobilization of the immune response for the purpose of therapeutic benefit. Preventative: infectious agents Therapeutic: cancer
General classes of vaccines Antibody response CD4+ T cells, B cells MHC class II-dependentCellular response cytotoxic CD8+ T cells, NK cells MHC class I-dependent
Classical success: polio virus • oral route of infection • initial replication in GI tract • vaccine: killed/attenuated virus • injected (Salk) • oral (Sabin)
Paroxysmal success: influenza • infects via airway • epithelial/systemic replication • killed/attenuated virus, protein • antibody to viral spike glycoprotein • (hemagglutinin, HA) confers protection HA genetic drift subverts antibody
Unmitigated failure: HIV • infects via anal/vaginal epithelia • replication/residence in immune cells • killed/attenuated virus • recombinant envelope glycoprotein • poor protection, cumbersome trials >80 million infected individuals/victims 3.1 million new cases/year in Africa alone
Why have HIV vaccines failed? • gp120 genetic drift subverts antibody • virus is rarely extracellular • wrong viral component, wrong delivery? • underdesigned? • or…overdesigned?
Typical antigen formulations • peptides bound to carriers (adjuvants) • recombinant proteins • killed or attenuated virus/bacteria • DNA or mRNA encoding protein antigen
Typical vaccine delivery vehicles • injection in adjuvant (skin, muscle) • oral, nasal • recombinant or synthetic viral vector • transformed microbial vector
Engineering rational vaccines • understand biology of target • understand biology of response bioengineering
Production of MHC class I & II-peptide complexes Virus-encoded proteins
“Cross presentation” of exogenous antigens on MHC class I: CD8 responses to extracellular agents
Dendritic cells initiate antigen-specific immune responses • most efficient of all APCs • high MHC class I, II & costimulators • efficient cross presentation • stimulate naïve T cells (CD4, CD8) • initiate Ag-specific immune responses All immunization strategies must target DCs
Immature: antigen capture Mature: antigen presentation
Multiple inducers of DC maturation immature DC mature DC Microbial products / TLR ligands Viral products Inflammatory cytokines Signaling receptors various T cell responses
Targeting DCs to elicit immunity: engineering requirements • The optimal delivery device… • will be targetable to selected DC populations • can be coupled to DC maturation agents (microbial, inflammatory, other?) • can accomodate any type of antigen • permits intracellular targeting (cross-presentation from cytosol favors cytotoxic T cell responses) • traceable (does it reach DCs, nodes?) • modular (permits efficient, small-scale trials) • synthetic, stable, orally available for global use